Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 193

1.

High-density lipoproteins and atherosclerosis.

Rader DJ.

Am J Cardiol. 2002 Oct 17;90(8A):62i-70i. Review.

PMID:
12419482
2.

Effects of oral contraceptives on lipid metabolism.

Krauss RM.

J Reprod Med. 1986 Jun;31(6 Suppl):549-50.

PMID:
3723487
3.

Lipoprotein subclasses and coronary artery calcium in postmenopausal women from the healthy women study.

Mackey RH, Kuller LH, Sutton-Tyrrell K, Evans RW, Holubkov R, Matthews KA.

Am J Cardiol. 2002 Oct 17;90(8A):71i-76i.

PMID:
12419483
4.

[Lipid risk factors and their role in the pathogenesis of atherosclerosis].

Vaverková H.

Vnitr Lek. 1996 Mar;42(3):191-6. Czech.

PMID:
8686209
5.

Hormone therapy, lipoprotein subclasses, and coronary calcification: the Healthy Women Study.

Mackey RH, Kuller LH, Sutton-Tyrrell K, Evans RW, Holubkov R, Matthews KA.

Arch Intern Med. 2005 Mar 14;165(5):510-5.

PMID:
15767525
6.

High-density lipoproteins: multifunctional vanguards of the cardiovascular system.

Marcil M, O'Connell B, Krimbou L, Genest J Jr.

Expert Rev Cardiovasc Ther. 2004 May;2(3):417-30. Review.

PMID:
15151487
7.

High-density lipoprotein metabolism: molecular targets for new therapies for atherosclerosis.

Kawashiri MA, Maugeais C, Rader DJ.

Curr Atheroscler Rep. 2000 Sep;2(5):363-72. Review.

PMID:
11122767
8.

Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.

Ribas V, Sánchez-Quesada JL, Antón R, Camacho M, Julve J, Escolà-Gil JC, Vila L, Ordóñez-Llanos J, Blanco-Vaca F.

Circ Res. 2004 Oct 15;95(8):789-97. Epub 2004 Sep 23.

10.

[Metabolism of atherogenic lipoproteins].

Beucler I, Turpin G.

Ann Med Interne (Paris). 2001 Apr;152(3):158-61. Review. French.

PMID:
11431574
11.

Effects of cardiovascular risk factors on coronary artery remodeling in patients with mild atherosclerosis.

Britten MB, Zeiher AM, Schächinger V.

Coron Artery Dis. 2003 Sep;14(6):415-22.

PMID:
12966261
12.

Role of fibric acid derivatives in the management of risk factors for coronary heart disease.

Després JP, Lemieux I, Robins SJ.

Drugs. 2004;64(19):2177-98. Review.

PMID:
15456334
13.

Diabetes, lipoproteins, and atherosclerosis.

Schonfeld G.

Metabolism. 1985 Dec;34(12 Suppl 1):45-50.

PMID:
3906360
14.

Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease.

Mudd JO, Borlaug BA, Johnston PV, Kral BG, Rouf R, Blumenthal RS, Kwiterovich PO Jr.

J Am Coll Cardiol. 2007 Oct 30;50(18):1735-41. Epub 2007 Oct 15.

15.

High density lipoproteins and coronary heart disease. Future prospects in gene therapy.

Fruchart JC, Duriez P.

Biochimie. 1998 Feb;80(2):167-72. Review.

PMID:
9587674
16.

Optimal therapy of low levels of high density lipoprotein-cholesterol.

Kashyap ML, Tavintharan S, Kamanna VS.

Am J Cardiovasc Drugs. 2003;3(1):53-65. Review.

PMID:
14727946
17.

How, when, and why to use apolipoprotein B in clinical practice.

Sniderman AD.

Am J Cardiol. 2002 Oct 17;90(8A):48i-54i. Review.

PMID:
12419480
19.

High-density lipoproteins: a therapeutic target for atherosclerotic cardiovascular disease.

Gomaraschi M, Calabresi L, Franceschini G.

Expert Opin Ther Targets. 2006 Aug;10(4):561-72. Review.

PMID:
16848692
20.

The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity.

Mandard S, Zandbergen F, van Straten E, Wahli W, Kuipers F, Müller M, Kersten S.

J Biol Chem. 2006 Jan 13;281(2):934-44. Epub 2005 Nov 4. Erratum in: J Biol Chem. 2006 Jul 28;281(30):21575.

Supplemental Content

Support Center